IL291465A - Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38 - Google Patents

Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38

Info

Publication number
IL291465A
IL291465A IL291465A IL29146522A IL291465A IL 291465 A IL291465 A IL 291465A IL 291465 A IL291465 A IL 291465A IL 29146522 A IL29146522 A IL 29146522A IL 291465 A IL291465 A IL 291465A
Authority
IL
Israel
Prior art keywords
engineered
compositions
antigen binding
binding domain
methods related
Prior art date
Application number
IL291465A
Other languages
Hebrew (he)
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of IL291465A publication Critical patent/IL291465A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL291465A 2019-09-18 2022-03-17 Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38 IL291465A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962902380P 2019-09-18 2019-09-18
PCT/US2020/051663 WO2021055876A1 (en) 2019-09-18 2020-09-18 COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CD38

Publications (1)

Publication Number Publication Date
IL291465A true IL291465A (en) 2022-05-01

Family

ID=74884204

Family Applications (1)

Application Number Title Priority Date Filing Date
IL291465A IL291465A (en) 2019-09-18 2022-03-17 Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38

Country Status (10)

Country Link
EP (1) EP4031166A1 (en)
JP (1) JP2022548925A (en)
KR (1) KR20220119362A (en)
CN (1) CN114786713A (en)
AU (1) AU2020351234A1 (en)
BR (1) BR112022005036A2 (en)
CA (1) CA3155187A1 (en)
IL (1) IL291465A (en)
MX (1) MX2022003316A (en)
WO (1) WO2021055876A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0618399B1 (en) * 2005-10-12 2023-10-03 Morphosys Ag HUMAN ANTI-CD38 SPECIFIC ANTIBODY, NUCLEIC ACID COMPOSITION, EXPRESSION VECTOR, PHARMACEUTICAL COMPOSITION, USE OF THE ANTIBODY AND USE OF A PHARMACEUTICAL COMPOSITION
PE20110707A1 (en) * 2008-10-14 2011-10-11 Genentech Inc IMMUNOGLOBULIN VARIANTS
EP3105317B1 (en) * 2014-02-14 2018-09-19 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
WO2015197582A1 (en) * 2014-06-27 2015-12-30 Innate Pharma Monomeric multispecific antigen binding proteins
JP2020514301A (en) * 2017-01-06 2020-05-21 モメンタ ファーマシューティカルズ インコーポレイテッド Compositions and methods relating to modified Fc antigen binding domain constructs

Also Published As

Publication number Publication date
JP2022548925A (en) 2022-11-22
BR112022005036A2 (en) 2022-07-05
WO2021055876A1 (en) 2021-03-25
MX2022003316A (en) 2022-07-11
KR20220119362A (en) 2022-08-29
CA3155187A1 (en) 2021-03-25
CN114786713A (en) 2022-07-22
AU2020351234A1 (en) 2022-04-28
EP4031166A1 (en) 2022-07-27

Similar Documents

Publication Publication Date Title
IL280046A (en) Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38
EP3565595A4 (en) Compositions and methods related to engineered fc-antigen binding domain constructs
IL263211B1 (en) Compositions and methods related to engineered fc constructs
PL3679141T3 (en) Methods and compositions for inhibiting expression of ldha
IL280044A (en) Compositions and methods related to engineered fc-antigen binding domain constructs
IL268815A (en) Compositions and methods for tumor transduction
SG10202107391YA (en) Compositions and methods related to engineered fc constructs
IL272103B2 (en) Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods of treating cancer
IL278701A (en) Heterocondensed pyridones compounds and their use as idh inhibitors
IL257458A (en) Dpep-1 binding compositions and methods of use
IL291509A (en) Modulation of microbiota compositions using targeted nucleases
IL279998A (en) Compositions and methods related to engineered fc-antigen binding domain constructs
IL280014A (en) Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ctla-4
EP3737384C0 (en) Methods and compositions for preventing and treating conditions related to alpha-synuclein
IL279999A (en) Compositions and methods related to engineered fc-antigen binding domain constructs
IL279989A (en) Compositions and methods related to engineered fc-antigen binding domain constructs
IL280038A (en) Compositions and methods related to engineered fc-antigen binding domain constructs targeted to pd-l1
IL279987A (en) Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ccr4
IL291465A (en) Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38
IL290219A (en) Compositions and methods for binding antibodies and inhibiting neutralizing antibodies
ZA202007107B (en) Compositions comprising pcsk9-binding molecules and methods of use
ZA202002763B (en) Fuel additive compositions, and method of use thereof
PL3577266T3 (en) Improved binder compositions and uses thereof
EP3902540A4 (en) Domperidone compositions and methods for treating depression